


KAZAN FEDERAL UNIVERSITY  
Institute of Fundamental Medicine and Biology

# Kazan Precision Medicine Workshop

ABSTRACT BOOK



September 10-12  
2018

## Table of contest

<b>Antibiotics inhibit ALDH1-high cancer stem cells in breast cancer model</b>	6
A.A. Akhunzianov, A.I. Khasanova, A.M. Gimranov, R.R. Miftakhova and A.A. Rizvanov	
<b>Nephron-sparing surgery in children with Wilms tumor using a single laparoscopic access</b>	7
N. R. Akramov A. K. Zakirov	
<b>Targeting cancer stem cells: implications for precision medicine in breast and testicular cancer</b>	8
Dr Cinzia Allegrucci	
<b>Antibiotic resistance and its transferability of probiotic <i>Lactobacillus</i> strains</b>	9
A. E. Anisimova, N. L. Bruslik and D. R. Yarullina	
<b>Study of the gene signature of differentially expressed in cisplatin resistant ovarian cancer cell line A2780A.</b>	10
A. Ataei, S. Rajabpour, A. Arab, A. Rizvanov	
<b>Acute Kidney Injury and Clear Cell Kidney Cancer</b>	11
Simone de Brot, Veronika Metzler, Leiping Fu2, Christopher Rolfe, Petra Westlake, Sue Thomas, Cinzia Allegrucci, Ryan Cardenas, Martin Johansson, Jenny Persson, Emad Rakha, Nataliya Blatt,6, Regina Miftakhova6, Albert Rizvanov6, Brian Robinson, Francesca Khani, David Gardner, Catrin Rutland, David Nanus, Lorraine Gudas, Nigel Mongan	
<b>Adhesion and colonization attributes of probiotic <i>Lactobacillus</i> strains</b>	12
N. L. Bruslik, S. A. Konnova, R. F. Fakhrullin and D. R. Yarullina	
<b>Production and analysis of stable mesenchymal stem cell culture with IL-2 overexpression</b>	13
D.S. Chulpanova, V.V. Solovyeva, L.G. Tazetdinova, S.K. Kletukhina, A.A. Rizvanov	
<b>Cytotoxic potential of new ribonuclease from <i>Bacillus altitudinis</i></b>	14
E. Dudkina, V. Ulyanova, P. Zelenikhin and O. Ilinskaya	
<b>Interaction of plant defensins with model membranes</b>	15
Elena Ermakova, Yuriy Zuev	
<b>Biodistribution of membrane vesicles in vivo</b>	16
M.O. Gomzikova, O.A. Neustroeva, S.K. Kletukhina, S.V. Kurbangaleeva, M.O. Mavlikeev, A.A. Rizvanov	
<b>Clinical significance of circulating tumor cell count in ovarian cancer</b>	17
D.U. Gafurbaeva, Yu.V. Filina, A.Yu. Fedotova, S.O. Gening, R.R. Miftakhova and A.A. Rizvanov	
<b>Cytotoxic activity of molecular containers on pillar[5]arene platform</b>	18
E Gruzdeva , D Shurpik , P Zelenikhin , I Stoikov	
<b>New Targets and Therapies for Kidney Cancer and Head and Neck Cancer.</b>	19
Lorraine Gudas, Johannes Van der Mijn, Kristian Laursen, Denise Minton, Nigel Mongan, Xiao-Han Tang, Theresa Scognamiglio, Francesca Khani, Maria Shevchuk, Lukas Dow, and David Nanus.	
<b>Development of biocompatible silica shells doped with magnetic nanoparticles</b>	20
I.R. Ishmukhametov, E.V. Rozhina, L.R. Nigamatzyanova, R.F. Fakhrullin	



<b>Development of yeast expression systems based on the gene-secreting beta-propeller bacterial phytase</b>	21
D. L. Itkina, A. D. Suleymanova, M. R. Sharipova	
<b>Targeting androgen co-regulators in prostate cancer</b>	22
JN Jeyapalan, VM Metzler, S de Brot, D Haigh, C Woodcock, J Whitchurch, BD Robinson, JL Persson, LJ Gudas, DM Heery, and NP Mongan	
<b>Efficacy of newly isolated Lactobacillus strains against antibiotic-resistant <i>Morganella morganii</i></b>	23
Ju S Judina, L. F. Minnullina, A. M. Mardanova and D. R. Yarullina	
<b>The trophic role of mesenchymal stem cells in co-culture with neuroblastoma cells</b>	24
K.V. Kitaeva, T.S. Prudnikov, A.A. Rizvanov, V.V. Solovyeva	
<b>Improvement of viscoelastic characteristics of polysaccharide-protein hydrogels by carbon nanotubes for the tasks of regenerative medicine</b>	25
A.O. Makarova, O.S. Zueva and Yu. F. Zuev	
<b>Targeting Tumour Hypoxic Response</b>	26
Alan McIntyre	
<b>Small molecule modulators of mutant p53 and their activity in genetically modified MCF7 cells</b>	27
R.N. Mingaleeva, R.M. Sayarova, R.R. Nazyrova, M. Baud, A.A. Rizvanov, R.R. Miftakhova, E.R. Bulatov	
<b>Essential partnerships: The key to improved patient outcomes</b>	28
Nigel P. Mongan	
<b>Chimeric sphere culture as a model of tumor-stromal cell interaction</b>	29
A.R. Rakhmatullina, S.F. Khaiboullina, R.N. Mingaleeva, Y.V. Filina, and A.A. Rizvanov and R.R. Miftakhova	
<b>Venous thrombosis among newborn infants under the conditions of intensive care unit</b>	30
E.L. Rashitova, I.N. Nurmeev	
<b>Magnetically-sensitive silica-coated shells for encapsulation of microorganisms</b>	31
L. R. Nigamatzyanova, F. S. Akhatova, S. A. Konnova, Y. V. Cherednichenko, S. F. Shayhulov	
<b>Sensitivity of the SCC61 and AsPC-1tumor cell to cisplatin under Physcion and PFI-3 inhibitors treatment</b>	32
V.S. Skripova, A.K. Nurgalieva and R.G. Kiyamova	
<b>Anticancer supramolecular system: Synthesis of thiacalix[4]arene aminobis(methylenephosphonac acids)</b>	33
K. S. Shibaeva, I. E. Shiabiev, A. A. Nazarova and I. I. Stoikov	
<b>Development of theranostic amino-decorated silica nanoparticles embedded with fluorescent anionic hexamolybdenum cluster complexes</b>	34
Gh. Shammas, R.F. Khairullin, Ju. G. Elistratova, A. R. Mukhametshina , K.A. Petrov, A.R. Mustafina and A.A. Rizvanov	
<b>Sensitivity of the SCC6 and AsPC-1tumor cell to cisplatin under Physcion and PFI-3 inhibitors treatment</b>	35
D. V. Savenkova, L. F. Minigulova , K. V. Havrysh , V. S. Skripova and R. G. Kiyamova	

<b>In vivo pattern recognition of heterogeneous N-glycoalbumins</b>	36
R. R. Sibgatullina, A. R. Kurbangalieva and K. Tanaka	
<b>Obtaining of a panel of pancreatic cancer cell lines expressing doxycycline inducible spCas9</b>	37
V.S. Skripova, A.K. Nurgalieva and R.G. Kiyamova	
<b>Gene Therapy: NMR Study of Interaction Some Water-Soluble Pillar[5]arenes Containing Amide and Ammonium Fragments With DNA Palindromic Decamer</b>	38
Polina V. Skvortsova, Evgeniya V. Subakaeva, Dzhigangir A. Faizullin, Dmitriy N. Shurpik, Pavel V. Zelenikhin, Ivan I. Stoikov, Bulat I. Khairutdinov, Yuriy F. Zuev	
<b>The effect of paclitaxel on ultrastructure of adipose-derived mesenchymal stem cells</b>	39
L. Tazetdinova, Z. Gilazieva, S. Arkhipova, V. Solovyeva, E. Alekseeva, A. Gallyamov, D. Chulpanova, A. Rizvanov	
<b>Evaluation of the effect of Nigericin on Lung Cancer cells</b>	40
Gulcin Tezcan; Zarema Gillazieva, Svetlana Sofronova, Svetlana Arkhipova, Nawar Sakr, Ekaterina Garanina, Konstantin Ivanov, Albert Rizvanov, Svetlana Khaiboullina	
<b>The role of the Musashi 2 protein in the regulation of the epidermal growth factor receptor (EGFR) level in non-small cell lung cancer.</b>	41
Y. A. Topchu, A. M. Mazitova, A. Y. Deneka, E. Y. Ratner, G. N. Khusainova, I.G. Serebriskii, Y. A. Bumber	
<b>Cancer immunology, bioinformatics and chemokine evidence link vaccines contaminated with animal proteins to autoimmune disease: a detailed look at Crohn's disease and Vitiligo</b>	42
Vinu Arumugham, M.V.Trushin	
<b>Evaluating efficacy of anti-CD19 CAR-T cells against CD19-positive 2D and 3D solid tumor models</b>	43
Aygul Valiullina, Regina Sayarova, Margarita Zhuravleva, Sevindzh Kletukhina, Alexey Petukhov, Emil Bulatov, Albert Rizvanov	
<b>The intestinal microbiota composition of constipated patients</b>	44
A. S. Volkova, A. A. Arzamasceva, D. R. Khusnutdinova, T. V. Grigoryeva, K.A. Sakulin, O. J. Karpukhin and D. R. Yarullina	
<b>Understanding the role of m<sup>6</sup>A Demethylase Proteins in Androgen and Estrogen signalling</b>	45
C. L. Woodcock , D. B. Haigh , V. M. Metzler, J. N. Jeyapalan , S. de Brot , J. Price , B. D. Robinson , N. Blatt , A. Rizvanov, E. Rakha , J. L. Persson <sup>6</sup> , L. J. Gudas , C. Rutland , R. Fray <sup>7</sup> and N. P. Mongan	
<b>Long noncoding RNAs as a potential diagnostic biomarkers for cervical cancer</b>	46
G.I. Sadikova, Yu.V. Filina, R.R. Miftakhova, N.A. Nigmatullina and A.A. Rizvanov	
<b>Epitranscriptomic determinants of aggressive prostate cancer</b>	47
C. Woodcock, D. Haigh, J.N. Jeyapalan, V.M. Metzler, S. de Brot, Nataliya Blatt, Albert Rizvanov, B.D. Robinson, J.L. Persson, L.J. Gudas <sup>6</sup> , Catrin Rutland, Rupert Fray <sup>6</sup> , and N.P. Mongan	

<b>Personalized Medicine: Matching cancer drugs with mechanism</b>	48
Anton Yuryev	
<b>Exon 7 WT1 mutation in patient with bilateral nephroblastoma and ambiguous genitalia</b>	49
A.K. Zakirov, N.R. Akramov	
<b>Evaluation of progastrin as a new plasma biomarker for cancer diagnosis</b>	50
M.A. Zolotykh, D.U. Gafurbaeva, Yu.V. Filina, G.I. Sadikova, A.A. Akhunzianov, R.R. Miftakhova, A.A. Rizvanov	
<b>Changes of activity of Caspase-3 after spinal cord injury in rat model</b>	51
E. Yamalitinova, J. Topchu, T. Povysheva, M. Baltin	



## Small molecule modulators of mutant p53 and their activity in genetically modified MCF7 cells

R.N. Mingaleeva<sup>1\*</sup>, R.M. Sayarova<sup>1</sup>, R.R. Nazyrova<sup>1</sup>, M. Baud<sup>2</sup>, A.A. Rizvanov<sup>1</sup>,  
R.R. Miftakhova<sup>1</sup>, E.R. Bulatov<sup>1</sup>

<sup>1</sup>*Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia*

<sup>2</sup>*University of Southampton, United Kingdom*

**Background:** In the struggle for obtaining evolutionary advantage cancer cells often acquire *TP53* gene mutations to evade apoptosis. Y220C is the ninth most common mutation for *TP53* gene and is annually observed in about 100,000 new diagnosed cancer cases worldwide. This mutation results in partial denaturation and loss of functions. Selective small molecules can stabilize the mutant protein and restore its impaired transcriptional functions. Aminobenzothiazole MB725 and its derivatives represent a highly promising scaffold for development of potent stabilisers/activators of p53(Y220C) mutant. In this study we explore how MB725 and its analog could effectively restore biological activity of p53(Y220C) mutant.

**Methods:** As one of the biological models we use breast carcinoma cell line MCF7 (p53wt) and two genetically modified variants, the first one has p53<sup>-/-</sup> status and the second one is p53-mutant (Y220C). Heterozygous MCF7 p53<sup>-/-</sup> cell line was obtained using CRISPR/Cas9 gene editing technology. MCF7 p53wt cells were stably transduced with lentivirus encoding *Cas9* gene, and then transfected with plasmid encoding *TP53*-specific sgRNA. *TP53* gene region in each population was DNA sequenced to confirm frameshift in proximity of Cas9-induced double-strand break. Cytotoxicity of MB725 and its analogs was assessed using MTS test. Effect of the compounds on cell proliferation and viability was monitored by xCELLigence real time cell analysis. Biological activity of the compounds is being investigated via analysis of p53-dependent gene expression by quantitative real-time reverse transcription PCR, quantitative analysis of alterations in intracellular protein levels by immunoblotting, cytofluorometric analysis of cell cycle and programmed cell death.

**Results:** According to the results, MB725 preferentially bind to recombinant p53(Y220C) mutant rather than p53wt. The viability of p53wt cells was not significantly changed after treatment with MB725.

**Conclusion:** These promising results will provide an important scientific groundwork for development of prospective personalized anti-tumor drugs.

**Acknowledgments:** The study was supported by Grant of the President of Russian Federation MK-4253.2018.4 to E.B., RFBR 18-34-00702 mol\_a Grant to R.S. and performed in accordance with Program of Competitive Growth of Kazan Federal University.

## Evaluating efficacy of anti-CD19 CAR-T cells against CD19-positive 2D and 3D solid tumor models

Aygul Valiullina<sup>1\*</sup>, Regina Sayarova<sup>1</sup>, Margarita Zhuravleva<sup>1</sup>, Sevindzh Kletukhina<sup>1</sup>, Alexey Petukhov<sup>1,2</sup>, Emil Bulatov<sup>1</sup>, Albert Rizvanov<sup>1</sup>

<sup>1</sup>*Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia*

<sup>2</sup>*Institute of Hematology, Almazov National Medical Research Centre, Saint Petersburg, Russia*

**Background:** Administration of CAR-T cells demonstrated remarkable success in treatment of hematologic malignancies (HM), however this novel cell therapy is significantly less efficient against solid tumors (ST). Poor clinical performance of CAR-T therapy in ST is primarily accounted for biological differences between ST and HM. Therefore it is important to develop models simulating *in vivo* conditions for testing effectiveness of CAR-T therapy against ST. In current study we evaluate anti-CD19 CAR-Ts against several 2D monolayer cell cultures and 3D bioprinted solid tumor models.

**Methods:** We constructed plasmid with 2nd-generation anti-CD19 CAR and also recombinant vector containing *CD19* gene under control of internal ubiquitin C promoter and puromycin resistance gene. T-cells obtained from healthy donor were activated and transduced with lentivirus. CD19-positive cells were generated by transduction of MDA231, MDA468, A431, H522 solid tumor cell lines with CD19\_p2a\_PuroR recombinant lentiviral vector and further incubation with puromycin to allow selection. After that anti-CD19 CAR-T cells were applied onto CD19-positive tumor cell 2D monolayer or 3D constructs bioprinted using hydrogel composition. Efficacy of anti-CD19 CAR-T cells was assessed using vitality assay, fluorescent and confocal microscopy.

**Results:** According to the results, anti-CD19 CAR-Ts were successfully used to fight CD19-positive cancer cells in 2D monolayer cell cultures and 3D bioprinted solid tumor models.

**Conclusion:** We propose that reported approach is suitable for screening and evaluating CAR-Ts against 2D and 3D solid tumor models.

**Acknowledgments:** Work performed in accordance with Program of Competitive Growth of Kazan Federal University.